Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3898MR)

This product GTTS-WQ3898MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3898MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10705MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ9718MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ9942MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ6409MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ9843MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ14310MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-7221
GTTS-WQ8978MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ13852MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-1193
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW